Vildagliptin (dihydrate)

Vildagliptin dihydrate (LAF237 dihydrate) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin dihydrate possesses excellent oral bioavailability and potent antihyperglycemic activity[1].

Product Specifications

CAS Number

[2133364-01-7]

Product Name Alternative

LAF237 (dihydrate) ; NVP-LAF 237 (dihydrate)

UNSPSC

12352005

Target

Apoptosis; Dipeptidyl Peptidase; Ferroptosis

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/Vildagliptin_dihydrate.html

Solubility

10 mM in DMSO

Smiles

O[C@@]1(C[C@H](C2)C3)C[C@H]3C[C@@]2(NCC(N4CCC[C@H]4C#N)=O)C1.O.O

Molecular Formula

C17H29N3O4

Molecular Weight

339.43

References & Citations

[1]Cheng Q, et al. Combination of the dipeptidyl peptidase IV inhibitor LAF237 [ (S) -1-[ (3-hydroxy-1-adamantyl) ammo]acetyl-2-cyanopyrrolidine] with the angiotensin II type 1 receptor antagonist valsartan [N- (1-oxopentyl) -N-[[2'- (1H-tetrazol-5-yl) -[1,1'-biphenyl]-4-yl]methyl]-L-valine] enhances pancreatic islet morphology and function in a mouse model of type 2 diabetes. J Pharmacol Exp Ther. 2008 Dec;327 (3) :683-91.|[2]Shen M, et al. The synergistic effect of valsartan and LAF237 [ (S) -1-[ (3-hydroxy-1-adamantyl) ammo]acetyl-2-cyanopyrrolidine] on vascular oxidative stress and inflammation in type 2 diabetic mice. Exp Diabetes Res. 2012;2012:146194.|[3]Abdelhamid AM, et al. Vildagliptin/Pioglitazone Combination Improved The Overall Glycemic Control In Type I Diabetic Rats. Can J Physiol Pharmacol. 2018 Mar 6. doi: 10.1139/cjpp-2017-0680.